Drug
IBI3003
IBI3003 is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_1
2
50%
Ph phase_3
1
25%
Ph phase_2
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Trials by Status
not_yet_recruiting125%
recruiting375%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_1
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT07336472
recruitingphase_3
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
NCT07623798
not_yet_recruitingphase_2
A Open-Label Phase in Participants With Multiple Myeloma
NCT07764861
recruitingphase_1
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06083207
Clinical Trials (4)
Showing 4 of 4 trials
NCT07336472Phase 1
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT07623798Phase 3
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
NCT07764861Phase 2
A Open-Label Phase in Participants With Multiple Myeloma
NCT06083207Phase 1
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4